Inhibition of EZH2 mitigates peritoneal fibrosis and lipid precipitation in peritoneal mesothelial cells mediated by klotho

References

• Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90–103.
   PubMed Web of Science ®Google Scholar
• Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–544.
   PubMed Web of Science ®Google Scholar
• Xue J, Li H, Zhou Q, et al. Comparison of peritoneal dialysis with hemodialysis on survival of diabetic patients with end-stage kidney disease: a meta-analysis of cohort studies. Ren Fail. 2019;41(1):521–531.
   PubMed Web of Science ®Google Scholar
• Zhao J, Shi J, Shan Y, et al. Asiaticoside inhibits TGF-β1-induced mesothelial-mesenchymal transition and oxidative stress via the Nrf2/HO-1 signaling pathway in the human peritoneal mesothelial cell line HMrSV5. Cell Mol Biol Lett. 2020;25:33.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zong M, Guan Q, et al. Protection of the peritoneal membrane by peritoneal dialysis effluent-derived mesenchymal stromal cells in a rat model of chronic peritoneal dialysis. Stem Cells Int. 2019;2019:8793640.
   PubMed Web of Science ®Google Scholar
• Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int. 2000;20(4_suppl):22–42.
   Web of Science ®Google Scholar
• Wang Q, Xu L, Zhang X, et al. GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1alpha in human peritoneal mesothelial cells treated with high glucose. Eur J Pharmacol. 2020;880:173076.
   PubMed Web of Science ®Google Scholar
• Khan MP, Singh AK, Joharapurkar AA, et al. Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by PGC-1α and skeletal muscle atrogenes: adipoR1 as a potential target for reversing Diabetes-Induced osteopenia. Diabetes. 2015;64(7):2609–2623.
   PubMed Web of Science ®Google Scholar
• Yin X, Zheng F, Pan Q, et al. Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. J Mol Endocrinol. 2015;55(3):169–181.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma KL, Liu J, et al. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 2015;52(6):1045–1056.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma KL, Liu J, et al. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab. 2015;308(12):E1140–E1148.
   PubMed Web of Science ®Google Scholar
• Muller CR, Leite A, Yokota R, et al. Post-weaning exposure to high-fat diet induces kidney lipid accumulation and function impairment in adult rats. Front Nutr. 2019;6:60.
   PubMed Web of Science ®Google Scholar
• Ma KL, Gong TK, Hu ZB, et al. Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease. BMC Nephrol. 2018;19(1):192.
   PubMedGoogle Scholar
• Hu ZB, Ma KL, Zhang Y, et al. Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2018;39(6):1022–1033.
   PubMed Web of Science ®Google Scholar
• Ma KL, Liu J, Ni J, et al. Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice via endothelial-mesenchymal transition. Int J Med Sci. 2013;10(4):420–426.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ma KL, Zhang Y, et al. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver Int. 2016;36(10):1525–1534.
   PubMed Web of Science ®Google Scholar
• Chang TI, Kang HY, Kim KS, et al. The effect of statin on epithelial-mesenchymal transition in peritoneal mesothelial cells. PLoS One. 2014;9(10):e109628.
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang CM, Feng Y, et al. Rapamycin inhibits peritoneal fibrosis by modifying lipid homeostasis in the peritoneum. Am J Transl Res. 2019;11(3):1473–1485.
   PubMed Web of Science ®Google Scholar
• Kuro-O M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.
   PubMed Web of Science ®Google Scholar
• Mencke R, Olauson H, Hillebrands JL. Effects of Klotho on fibrosis and cancer: a renal focus on mechanisms and therapeutic strategies. Adv Drug Deliv Rev. 2017;121:85–100.
   PubMed Web of Science ®Google Scholar
• Hu MC, Shi M, Cho HJ, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol. 2015;26(6):1290–1302.
   PubMed Web of Science ®Google Scholar
• Barnes JW, Duncan D, Helton S, et al. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019;317(1):L141–L154.
   PubMed Web of Science ®Google Scholar
• Kurundkar A, Thannickal VJ. Redox mechanisms in age-related lung fibrosis. Redox Biol. 2016;9:67–76.
   PubMed Web of Science ®Google Scholar
• Kim JH, Hwang KH, Park KS, et al. Biological role of anti-aging protein klotho. J Lifestyle Med. 2015;5(1):1–6.
   PubMedGoogle Scholar
• Shen Y, Yan Y, Lu L, et al. Klotho ameliorates hydrogen peroxide-induced oxidative injury in TCMK-1 cells. Int Urol Nephrol. 2018;50(4):787–798.
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen Y, Shen S, et al. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis. Aging. 2020;12(7):5812–5831.
   PubMedGoogle Scholar
• Kadoya H, Satoh M, Nishi Y, et al. Klotho is a novel therapeutic target in peritoneal fibrosis via wnt signaling inhibition. Nephrol Dial Transplant. 2020;35(5):773–781.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang X, Xu Y, et al. RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis. Oncotarget. 2018;9(18):14397–14412.
   PubMedGoogle Scholar
• Zhou Q, Bajo MA, DEL PG, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515–524.
   PubMed Web of Science ®Google Scholar
• Shang J, He Q, Chen Y, et al. miR-15a-5p suppresses inflammation and fibrosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA. J Cell Physiol. 2019;234(6):9746–9755.
   PubMed Web of Science ®Google Scholar
• Lau-Corona D, Bae WK, Hennighausen L, et al. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. PLoS Genet. 2020;16(5):e1008796.
   PubMed Web of Science ®Google Scholar
• Eun LJ, Kim JE, Lee MH, et al. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab Invest. 2016;96(5):547–560.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen L, Pandak WM, et al. High glucose induces lipid accumulation via 25-Hydroxycholesterol DNA-CpG methylation. iScience. 2020;23(5):101102.
   PubMed Web of Science ®Google Scholar
• Haslinger B, Kleemann R, Toet KH, et al. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 2003;63(6):2065–2074.
   PubMed Web of Science ®Google Scholar
• Zhang LM, Zhang J, Zhang Y, et al. Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression. Biomed Pharmacother. 2019;113:108756.
   PubMed Web of Science ®Google Scholar
• Shin IS, Shin HK, Kim JC, et al. Role of Klotho, an antiaging protein, in pulmonary fibrosis. Arch Toxicol. 2015;89(5):785–795.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Nian Q, Chen G, et al. Klotho alleviates lung injury caused by paraquat via suppressing ROS/P38 MAPK-regulated inflammatory responses and apoptosis. Oxid Med Cell Longev. 2020;2020:1–13.
   Web of Science ®Google Scholar
• Ding J, Tang Q, Luo B, et al. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway. Eur J Pharmacol. 2019;859:172549.
   PubMed Web of Science ®Google Scholar
• Ritchie M, Hanouneh IA, Noureddin M, et al. Fibroblast growth factor (FGF)-21 based therapies: a magic bullet for nonalcoholic fatty liver disease (NAFLD)?. Expert Opin Investig Drugs. 2020;29(2):197–204.
   PubMed Web of Science ®Google Scholar